Kalaris Therapeutics (NASDAQ:KLRS) announced the appointment of Leone Patterson to its board of directors (BOD) as chair of the audit committee.
Ms. Patterson brings extensive experience as a biotech executive and board member to this role. Currently serving as Symework’s EVP, CBO, and CFO, she is responsible for corporate finance and accounting, business development, and other operational functions.
David Hallal, chairman of the Kalaris BOD, stated, “We’re delighted to welcome Leone as chair of the board’s audit committee. Leone is joining us at the pinnacle of her career as a senior financial executive in biotech with strong strategic and operational capabilities. Leone will be an outstanding addition to our BOD. We look forward to her contributions and expertise as we continue to develop and grow Kalaris.”
Ms. Patterson commented, “I am thrilled to join Kalaris Therapeutics’ BOD. The company’s lead asset along with its experienced management team and board, represent a significant opportunity to evolve the treatment paradigm in retinal diseases.”
